320 drugs transferred out of health insurance (with list)

August 10, the industry news, 320 drugs from January 1, 2021 transferred out of a provincial health insurance directory, into self-cost drugs, requiring doctors to choose alternative drugs for patients as soon as possible.
information shows that the document listed 320 drugs for the original province to supplement the drug catalog, non-national health insurance drug catalog, use to the end of 2020, January 1, 2021 to transfer out of the health insurance directory for self-expense, please doctors know, as soon as possible for patients to choose alternative drugs, and do a good job of interpretation.
documents show that all drugs not included in the National List of Essential Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drugs (2019 edition) are transferred out in one go (except for ethnic medicines) in the provincial medical insurance catalogue, and the National List of Essential Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drugs (2019 edition) will be implemented uniformly from 1 January 2021.
the co-ordination areas shall not make their own catalogues or increase the number of drugs in the catalogues by changing methods, or adjust the drugs in the catalogues themselves and limit the scope of payment.
of the information system maintenance and commissioning by December 15, 2020 by the various co-ordinating regional agencies, designated medical institutions and major disease insurance contractors.
According to industry sources, 320 drugs were transferred this time, including 180 Western medicines and 140 Chinese medicines, including Azasjong injections, quercetin oral liquids, zinc glucose acid oral liquids, bivalent injections, mendonine Potassium injection, erythromycin slow release control agent type, libawelin oral liquid agent and other Western medicine;
The State Health Insurance Administration has issued a notice requiring that by the end of June the state key monitoring varieties out of the catalog, and complete 40% of the provincial varieties of digestion, according to incomplete statistics, there are currently 17 provinces including Gansu, Ningxia, Xinjiang, Guangxi, Zhejiang, including the implementation of the landing.
, Tibet, Yunnan, Hebei, Shanghai, Anhui and other places only announced the transfer of varieties before July 2020, not the different stages of the transfer of varieties.
the provinces circulating in the industry, will be 320 varieties all transferred out, no longer according to three years of time each year, enough to see its strength, strong determination.
provincial supplement, involving more than 100 billion market according to Fengyun drug talk statistics, the national provincial health insurance supplement products more than 10,000 times, the preliminary estimate of the cumulative use of medical insurance amount of products at least 100 billion, from the total, the number of chemical and Chinese medicine provincial increase is basically 1:1.
There has been a view in the industry that for local supplement varieties, the requirements of all places strictly in accordance with the national basic medical insurance drug catalog implementation, in principle, not to develop their own or use a variety of methods to increase the catalog of drugs, the requirement reduces the space for rent-seeking, all places use a medical insurance catalog, products into the national medical insurance catalog on the importance of pharmaceutical enterprises increased.
to some extent, previously local tenders were made for the protection of local enterprises, or the varieties produced by local enterprises were added to the local health insurance catalogue.
addition to this, the elimination of provincial additions would also help to break the chain of local interests.
, deputy director of the National Health And Safety Commission, pointed out that allowing local drug supplements is a transitional measure in the early stages of system construction.
, author of the paper, believes that all products that have been called out of the health insurance catalogue are "double-edged swords" for all enterprises and pharmaceutical natural persons.
this will bring pharmaceutical representatives and agents "performance" and "psychological" double pressure, in the outbreak and the national harvest, the already great pressure, the end of the pressure is also "customary."
if their own varieties are transferred out of the province to supplement, the end of the task to complete the pressure can be imagined, in the long run the province's drug pattern will change.
the same time, if transferred out of the province to add varieties of competition, will usher in a new round of market opportunities.
Which varieties were spared although explicitly requested to cancel the provincial supplement, but the document also gave pharmaceutical companies and medical institutions a three-year buffer period, on the one hand, to consider changes in local drug habits;
if you don't set a buffer period, the problem of supply handling in existing medical institutions can be very difficult.
three-year buffer period, the purpose is to let out there is a chance to come in again, as long as the standard of the base drug catalog, do a good job of secondary research and development, evidence-based medicine, or can re-enter health insurance.
August 3, the State Health Insurance Administration issued the 2020 National Health Insurance Drug Catalog Adjustment Work Programme (Draft for Comments), which identifies seven types of drugs that can be included in the 2020 National Health Insurance Directory.
, the program shows that by the end of 2019, more than five provincial health insurance list of drugs, excluding the first batch of key monitoring drugs.
original provisions of the provincial medical insurance catalogue class B drugs, should be gradually digested within 3 years.
2020 rules mean giving these provincial supplements a chance to get into state-level health insurance.
some research institutions believe that after the adjustment of the local medical insurance catalogue, clinical abuse is obvious, the price is higher, some auxiliary drugs or is affected in the first place.
2020 draft for comments through the "5 provinces in common" way, allowing some local health insurance varieties into the national health insurance directory, as far as possible to balance clinical needs, health insurance charges and local interests, can pay attention to the health insurance catalog after the results of the negotiation of local health insurance varieties "upgrade" situation.
the rules shared by the five provinces, so that a number of large-selling provincial supplement varieties ushered in a new turning point.
According to incomplete statistics, five varieties were added in more than 20 provinces, including serum pills, inosa, cephalosporine tamadan, and glycosin peptides;
the following are the province to add more than 10 129 varieties (statistics are large, inevitably omission, hope you understand) attached: 320 drugs, was transferred out of health insurance.